On February 19, 2026 Havah Therapeutics, a clinical-stage biopharmaceutical company pioneering androgen receptor (AR) agonist therapies for hormone receptor positive breast cancer, reported that Professor Stephen Birrell MD, PhD, will deliver a presentation titled "HAV-088: Bending Evolution to the Will of Medicine" at the upcoming RiseUp for Breast Cancer and Women’s Health Conference in San Francisco.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Key highlights of the presentation include:
A translational framework for "endocrine steering" of hormonally active breast tissue using HAV-088, an androgen receptor (AR) agonist
An overview of Havah’s prospectively registered pilot, randomized controlled trial comparing HAV-088 with tamoxifen in high-risk premenopausal women with dense breasts and marked MRI background parenchymal enhancement (BPE)
An integrated evidence chain linking drug exposure, spatial tissue biology, intracrine hormone metabolism, and imaging biomarkers
Details for the presentation are as follows:
RiseUp For Breast Cancer and Women’s Health Conference
February 19-21, 2026
Hotel Nikko, San Francisco, CA
Presentation Title: HAV-088: Bending Evolution to the Will of Medicine
Presenter: Professor Stephen Birrell, MD, PhD
Date/Time: Friday, February 20, 12:10 Pacific Time
(Press release, HavaH Therapeutics, FEB 19, 2026, View Source [SID1234662811])